Opioid company rumoured to be in talks to offer $10-12 billion to settle US claims


  • Mary Corcoran
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The pharmaceutical company behind OxyContin, Purdue Pharma, and its owners are in talks to offer in the region of $10-12 billion (approx €9-10.8 billion) to settle more than 2,000 lawsuits against the company in the US, according to NBC News. The company faces allegations that it was at least partly responsible for the opioid crisis in the US. 

The media outlet reported this week that the “potential deal” was part of confidential conversations and was discussed by Purdue's lawyers at a meeting on August 20, according to two people familiar with the mediation.

In a statement to NBC News, the company said: "While Purdue Pharma is prepared to defend itself vigorously in the opioid litigation, the company has made clear that it sees little good coming from years of wasteful litigation and appeals.

“The people and communities affected by the opioid crisis need help now. Purdue believes a constructive global resolution is the best path forward, and the company is actively working with the state attorneys general and other plaintiffs to achieve this outcome."

Official figures from the US Centers for Disease Control and Prevention show almost 400,000 people died from an overdose involving any opioid between 1999 and 2017.